These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28139129)

  • 1. [Oral antidiabetic drugs in treatment of type 1 diabetes mellitus].
    Brunerová L; Brož J
    Vnitr Lek; 2016; 62(12):998-1003. PubMed ID: 28139129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
    Liu Y; Hong T
    Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New therapies for diabetes: beyond injectable insulin and oral antidiabetics].
    Alfonso JE; Ariza ID
    Rev Assoc Med Bras (1992); 2008; 54(5):447-54. PubMed ID: 18989567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
    Pratley RE; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Thomsen AB; Søndergaard RE; Davies M;
    Lancet; 2010 Apr; 375(9724):1447-56. PubMed ID: 20417856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New antidiabetic drugs: current status and future prospects - a review of the literature].
    Baranowska A; Stefanowicz-Rutkowska M; Matuszewski W; Bandurska-Stankiewicz E
    Wiad Lek; 2018; 71(8):1588-1598. PubMed ID: 30684345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea.
    Lozano-Ortega G; Goring S; Bennett HA; Bergenheim K; Sternhufvud C; Mukherjee J
    Curr Med Res Opin; 2016 May; 32(5):807-16. PubMed ID: 26700585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of Type 2 Diabetes: a Practical Approach].
    Donath M
    Praxis (Bern 1994); 2016 Jun; 105(12):699-702. PubMed ID: 27269776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of antidiabetic drugs in the U.S., 2003-2012.
    Hampp C; Borders-Hemphill V; Moeny DG; Wysowski DK
    Diabetes Care; 2014; 37(5):1367-74. PubMed ID: 24623020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 14. [New oral hypoglycemic drugs in diabetic kidney disease].
    Dylewska M; Graczyk M
    Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors.
    DeGeeter M; Williamson B
    J Pharm Pract; 2016 Apr; 29(2):144-59. PubMed ID: 25312263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists?
    Jax T
    Clin Res Cardiol; 2009 Feb; 98(2):75-9. PubMed ID: 18853087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of anti-diabetic therapy on overweight/obesity and dyslipidemia: traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2013 Dec; 14(12 Suppl):15-25. PubMed ID: 24362783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
    Dai X; Wang H; Jing Z; Fu P
    Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Which oral agent to use when metformin is no longer effective?
    Bannon M
    QJM; 2011 Mar; 104(3):183-4. PubMed ID: 21330402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.